BEOVU DIN 02496976
Status: Marketed
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada record
| Active ingredient(s) | BROLUCIZUMAB 6 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravitreal |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | S01LA06 BROLUCIZUMAB |
|---|
| Original market date | 15-May-2020 |
|---|
| Current status date | 15-May-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BROLUCIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02496984 | BEOVU | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | BROLUCIZUMAB 6 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 23336 | 2020-03-12 | New Drug Submission (NDS) | |
Request a quote for BEOVU
How to read a Canadian DIN record